Evidence map›Paper›PMID 38781160›Full record

ArticlePloS one2024

Spectrum of infection and outcomes in individuals with Candida auris infection in Qatar.

Jameela A Al Ajmi, Aimon B Malik, Hanaa Nafady-Hego, Fathima Hanana, Joji Abraham, Humberto G Garcell, Ghada Hudaib, Walid Al-Wali, Faiha Eltayeb, Sherin Shams and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Consensus paper onTurkish journal of medical sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jameela A Al AjmiCorporate Quality and Patient Safety Department, Hamad Medical Corporation, Doha, Qatar.
Aimon B MalikCorporate Quality and Patient Safety Department, Hamad Medical Corporation, Doha, Qatar.
Hanaa Nafady-HegoMicrobiology and Immunology, Faculty of Medicine, Assiut University, Assiut, Egypt.ORCID 0000-0002-5562-0245
Fathima HananaCorporate Quality and Patient Safety Department, Hamad Medical Corporation, Doha, Qatar.
Joji AbrahamCorporate Quality and Patient Safety Department, Hamad Medical Corporation, Doha, Qatar.
Humberto G GarcellInfection Prevention and Control Department, The Cuban Hospital, Dukhan, Qatar.
Ghada HudaibCorporate Quality and Patient Safety Department, Hamad Medical Corporation, Doha, Qatar.
Walid Al-WaliDepartment of Microbiology and Laboratory Medicine, Hamad Medical Corporation, Doha, Qatar.
Faiha EltayebDepartment of Microbiology and Laboratory Medicine, Hamad Medical Corporation, Doha, Qatar.
Sherin ShamsCorporate Quality and Patient Safety Department, Hamad Medical Corporation, Doha, Qatar.
Anil G ThomasCorporate Quality and Patient Safety Department, Hamad Medical Corporation, Doha, Qatar.
Samah SaleemCorporate Quality and Patient Safety Department, Hamad Medical Corporation, Doha, Qatar.
Abdul-Badi Abou-SamraCorporate Quality and Patient Safety Department, Hamad Medical Corporation, Doha, Qatar.ORCID 0000-0001-8735-1142
Adeel A ButtCorporate Quality and Patient Safety Department, Hamad Medical Corporation, Doha, Qatar.ORCID 0000-0002-1118-1826

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe investigated the spectrum of infection and risk factors for invasive fungal disease due to Candida auris (CA) in Qatar.

methodsWe performed structured chart reviews on individuals with any positive CA culture between May 2019 and December 2022 at three tertiary care hospitals in Qatar. Invasive CA disease (ICAD) was defined as a positive sterile site culture, or any positive culture for CA with appropriate antifungal prescription. Main outcomes included proportion of individuals who developed ICAD among those with positive cultures, and 30-day/in-hospital mortality.

resultsAmong 331 eligible individuals, median age was 56 years, 83.1% were male, 70.7% were non-Qataris, and 37.5% had ≥ 3 comorbidities at baseline. Overall, 86.4% were deemed to have colonization and 13.6% developed ICAD. Those with ICAD were more likely to have invasive central venous or urinary catheterization and mechanical ventilation. Individuals with ICAD had longer prior ICU stay (16 vs 26 days, P = 0.002), and longer hospital length of stay (63 vs. 43 days; P = 0.003), and higher 30-day mortality (38% vs. 14%; P<0.001). In multivariable regression analysis, only mechanical ventilation was associated with a higher risk of ICAD (OR 3.33, 95% CI 1.09-10.17).

conclusionInvasive Candida auris Disease is associated with longer hospital stay and higher mortality. Severely ill persons on mechanical ventilation should be especially monitored for development of ICAD.

Indexed as

Hospital MortalityAdultAgedAntifungal AgentsCandidaCandida aurisCandidiasisCandidiasis, InvasiveFemaleHumansLength of StayMaleMiddle AgedQatarRetrospective StudiesRisk FactorsAntifungal Agents

Identifiers

PMID38781160
PMCPMC11115301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.